1. Home
  2. FGI vs GLTO Comparison

FGI vs GLTO Comparison

Compare FGI & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo FGI Industries Ltd.

FGI

FGI Industries Ltd.

HOLD

Current Price

$6.03

Market Cap

14.0M

Sector

Industrials

ML Signal

HOLD

Logo Galecto Inc.

GLTO

Galecto Inc.

HOLD

Current Price

$31.19

Market Cap

23.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FGI
GLTO
Founded
1987
2011
Country
United States
Denmark
Employees
N/A
N/A
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.0M
23.7M
IPO Year
2022
2020

Fundamental Metrics

Financial Performance
Metric
FGI
GLTO
Price
$6.03
$31.19
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$36.00
AVG Volume (30 Days)
59.3K
207.8K
Earning Date
11-14-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$135,654,095.00
N/A
Revenue This Year
$3.80
N/A
Revenue Next Year
$6.26
N/A
P/E Ratio
N/A
N/A
Revenue Growth
6.66
N/A
52 Week Low
$2.28
$2.01
52 Week High
$12.62
$33.60

Technical Indicators

Market Signals
Indicator
FGI
GLTO
Relative Strength Index (RSI) 48.81 74.33
Support Level $7.17 $25.60
Resistance Level $9.00 $29.97
Average True Range (ATR) 1.32 2.93
MACD 0.10 0.83
Stochastic Oscillator 22.21 98.78

Price Performance

Historical Comparison
FGI
GLTO

About FGI FGI Industries Ltd.

FGI Industries Ltd is a supplier of kitchen and bath products. The company is business to business supplier of bath and kitchen products to large retail, wholesale, commercial, and specialty channel customers around the globe. The company offers products that fall into four categories: Sanitaryware, Bath Furniture, Shower Systems and Other. The company generates the majority of its revenue from the sale of Sanitaryware products. Geographically, the company generates the majority of its revenue from the United States, followed by Canada and Europe.

About GLTO Galecto Inc.

Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.

Share on Social Networks: